ISSN: 1838-7640Theranostics
Global reach, higher impact
Theranostics 2020; 10(4):1708-1718. doi:10.7150/thno.38339 This issue Cite
Review
Molecular imaging biomarkers for immune checkpoint inhibitor therapy
1. Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
2. Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
3. Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
4. Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Citation:
van de Donk PP, Kist de Ruijter L, Lub-de Hooge MN, Brouwers AH, van der Wekken AJ, Oosting SF, Fehrmann RSN, de Groot DJA, de Vries EGE. Molecular imaging biomarkers for immune checkpoint inhibitor therapy. Theranostics 2020; 10(4):1708-1718. doi:10.7150/thno.38339. https://www.thno.org/v10p1708.htm
Other stylesAbstract
Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients' immune system, resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple different tumor types. Unfortunately, a substantial group of patients do not respond to ICIs. Molecular imaging, using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell characteristics and might support patient selection or response evaluations for ICI therapies. In this review, recent studies with 18F-fluorodeoxyglucose-PET imaging, imaging of immune checkpoints and imaging of immune cells will be discussed. These studies are until now mainly exploratory, but the first results suggest that molecular imaging biomarkers could have a role in the evaluation of ICI therapy.
Keywords: molecular imaging, biomarkers, positron emitting tomography, immune checkpoint inhibitor, immunotherapy.
Citation styles
APA
van de Donk, P.P., Kist de Ruijter, L., Lub-de Hooge, M.N., Brouwers, A.H., van der Wekken, A.J., Oosting, S.F., Fehrmann, R.SN., de Groot, D.J.A., de Vries, E.GE. (2020). Molecular imaging biomarkers for immune checkpoint inhibitor therapy. Theranostics, 10(4), 1708-1718. https://doi.org/10.7150/thno.38339.
ACS
van de Donk, P.P.; Kist de Ruijter, L.; Lub-de Hooge, M.N.; Brouwers, A.H.; van der Wekken, A.J.; Oosting, S.F.; Fehrmann, R.SN.; de Groot, D.J.A.; de Vries, E.GE. Molecular imaging biomarkers for immune checkpoint inhibitor therapy. Theranostics 2020, 10 (4), 1708-1718. DOI: 10.7150/thno.38339.
NLM
van de Donk PP, Kist de Ruijter L, Lub-de Hooge MN, Brouwers AH, van der Wekken AJ, Oosting SF, Fehrmann RSN, de Groot DJA, de Vries EGE. Molecular imaging biomarkers for immune checkpoint inhibitor therapy. Theranostics 2020; 10(4):1708-1718. doi:10.7150/thno.38339. https://www.thno.org/v10p1708.htm
CSE
van de Donk PP, Kist de Ruijter L, Lub-de Hooge MN, Brouwers AH, van der Wekken AJ, Oosting SF, Fehrmann RSN, de Groot DJA, de Vries EGE. 2020. Molecular imaging biomarkers for immune checkpoint inhibitor therapy. Theranostics. 10(4):1708-1718.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.